Status:
UNKNOWN
Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborating Sponsors:
Chinese PLA General Hospital
Peking University People's Hospital
Conditions:
Cerebrovascular Disease
Eligibility:
All Genders
14-80 years
Phase:
PHASE1
Brief Summary
To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.
Detailed Description
Ischemic stroke is a leading cause of disability and death worldwide. Antiplatelet treatment is one of treatment strategies in secondary stroke prevention for patients with non-cardioemoblism etiology...
Eligibility Criteria
Inclusion
- 14 years of age or older
- no gender aspirin or clopidogrel for ischemic cerebrovascular disease Primary or secondary prevention of ischemic stroke patients
- The researcher (or principal) signs the informed consent form
Exclusion
- Significant head trauma or stroke in the last 3 months
- 3 months to accept intracranial, spinal surgery or other parts of large surgery
- In the last week there is an incurable part of the artery puncture
- Acute bleeding constitution, including platelet count \<100 × 109 / L or other conditions
- within the last 48h heparin treatment, APTT higher than the upper limit of normal range
- Oral anticoagulant: INR\> 1.7 or PT\> 15s
- The presence of intracranial tumors, aneurysms or arteriovenous malformations
- Patients with any of the following cardioembolic-related illnesses are identified: rheumatic mitral or aortic stenosis, prosthetic heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, Open foramen ovale, left ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial endocarditis, or any other cardiovascular disease not suitable for enrollment; (as determined by the investigator)
- Severe liver and kidney dysfunction
- Life expectancy is less than 1 year
- Pregnant or lactating women
- Participating in other clinical studies, or have participated in other clinical studies within the 3 months before enrolling, or have already participated in this research
- Allergic or intolerant to aspirin or clopidogrel
- There are stomach lesions, such as gastritis, gastric ulcer and so on
- Do not want to follow-up or poor treatment compliance
Key Trial Info
Start Date :
April 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT03471169
Start Date
April 1 2017
End Date
December 1 2018
Last Update
March 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
XuanWu hospital
Beijing, Xicheng, China, 100053